admin – Page 7897 – Get News Story

Why professional resume writers challenge recent anti-resume claims

Vancouver, BC – December 20, 2023 – Recently, a prominent career influencer argued against using resumes in job searches, Certified Professional Resume Writer Tim Cunningham challenges those claims, and highlights the indispensable role that well-crafted resumes play in today’s job searches.

While the influencer emphasized networking over resume submissions, Tim Cunningham, Founder of Fast & Focused Resume Service, contends that this perspective overlooks several factors. “While networking is best when you can do it, sometimes a well-crafted resume is the only option, especially when connections are limited, or time constraints press.”

The recent claims against resumes include this one: “A resume is a dumb piece of paper.” In response, Cunningham counters: “Resumes are not mere documents; they are strategic tools that articulate your skills, achievements, and potential contributions. Contrary to another claim that writing your own resume is the best way to set forth your unique qualities, Cunningham replies that most people don’t remember the full range of their successes. He believes one of the major ways “professional assistance empowers clients is by helping them recall forgotten accomplishments that showcase their strengths.” For Cunningham, that involves techniques learned as a child watching his TV journalist father. “That time spent watching him work helps me notice when somebody has something more to tell than they think they do. So, I circle back until I get the success stories I’m seeking,” he says. “One of those ‘success stories’ prompted five interviews in sixteen days.”

Cunningham regards his background in financial supervision, purchasing, and sales as a crucial advantage As he puts it: “To create resumes that generate interviews, it’s important to understand operational realities in ways that go beyond the job descriptions. I once delivered a C-level interview by asking a client if he’d experienced a kind of challenge not mentioned in the job ad.”

Finally, Cunningham’s approach disputes the notion that resumes lack value by stating, “With thousands of applicants applying for a single job, a well-structured resume is often the key to capturing a manager’s attention within the first few seconds reading time. It’s not just about listing achievements; it’s about presenting them in a way that prompts interview invitations.” Cunningham knows his clients can’t expect a manager to read more than the first third of the resume’s first page. That’s why he has several strategies designed to grab a manager’s attention and not let go until the resume rests in the “To Be Interviewed” pile.

Cunningham has a proven track record of delivering results, reducing job search durations, and securing interviews for clients at all levels and industries. Testimonials from CEOs, COOs, and other executives attest to his effectiveness.

About Tim Cunningham:

Fast & Focused Resume Service Founder, Tim Cunningham is a Certified Professional Resume Writer who combines “deep business operations knowledge and professional interviewing techniques to prepare outstanding resumes that leverage accomplishments into great career opportunities and make job searches shorter.”

To learn more about Tim’s resume packages and LinkedIn coaching, visit https://ffresume.com

Media Contact
Company Name: Fast & Focused Resume Service
Contact Person: Tim Cunningham
Email: Send Email
City: Vancouver
State: BC
Country: Canada
Website: https://ffresume.com

YourKeyCoach unveils comprehensive career coaching services for tech professionals

Houston, TX – December 20, 2023 – YourKeyCoach, founded by Keanna Carter, is proud to announce the recent launch of its innovative career coaching services tailored for new grads to senior-level professionals in the tech industry. Leveraging Keanna’s extensive experience at renowned companies like Facebook and Google, YourKeyCoach aims to empower individuals in navigating their career journey, securing new roles, and unlocking their full potential.

Keanna Carter, a dedicated career coach with a background as a recruiter for the past five years, draws from her rich experience to guide individuals in crafting standout resumes, optimizing LinkedIn profiles, excelling in interviews, negotiating competitive salaries, and achieving overall career success.

“I am excited to unveil YourKeyCoach—an empowering service crafted to guide you on your path to success. Motivated by my own experience navigating the challenges of tech layoffs in March, I recognized the opportune moment to transition into career coaching, leveraging the valuable insights I’ve acquired over the past five years in the dynamic realm of tech recruiting.” stated Keanna Carter.

YourKeyCoach is founded on the belief that while technical skills are essential, one’s network is the greatest asset. Keanna is committed to guiding individuals in finding their niche and achieving success, whether it’s in tech or any other field. With a global perspective from her current base in the vibrant city of Mexico City, Keanna brings a unique blend of insights and experiences to the table.

YourKeyCoach offers a range of services designed to address the diverse needs of tech professionals:

Resume Writing: Crafted by YourKeyCoach, standout resumes highlight strengths and make a lasting impression on employers. The service differentiates clients from other candidates, increasing their chances of success.

LinkedIn Optimization: YourKeyCoach optimizes LinkedIn profiles for a stronger online presence, updating pictures, summaries, and accomplishments. Engagement with relevant communities unlocks full potential and reveals exciting opportunities.

Interview Preparation: Tailored coaching sessions empower clients to navigate interviews with confidence, answer tough questions, and develop a personal brand. The goal is to increase the likelihood of securing the desired job.

Salary Negotiation: YourKeyCoach is dedicated to empowering clients throughout their professional journey by providing tools, knowledge, and support to navigate the salary negotiation process with confidence.

“At YourKeyCoach, clients are guided by a seasoned professional with a proven track record in HR, providing strategic insights that pave the way to success. Our commitment extends to offering personalized solutions, intricately aligned with individual career aspirations. From securing dream jobs to optimizing online presence, mastering interviews, and negotiating deserving salaries, YourKeyCoach is dedicated to unlocking the full potential of your professional journey.” She added in.

YourKeyCoach prides itself on a partnership built on understanding individual needs. Keanna emphasizes, “Your success is my priority, and I’m dedicated to providing support and guidance at every step of your career journey.”

About Keanna Carter:

As a dedicated career coach with seven years of experience in the dynamic tech industry, including five years as a recruiter, Keanna Carter’s mission is to unlock your career potential. Born in the Philippines, raised under the Californian sun, and currently thriving in the heart of Mexico City, Keanna’s journey from Facebook to Google and across the tech hub of the Bay Area to the colorful streets of Mexico City equips her with a unique set of experiences that she channels into her coaching.

For more information about YourKeyCoach and to explore the services offered, please visit https://www.yourkeycoach.com

Media Contact
Company Name: YourKeyCoach
Contact Person: Keanna Carter
Email: Send Email
City: Houston
State: TX
Country: United States
Website: https://www.yourkeycoach.com

Neuromyelitis Optica Spectrum Disorder Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Remegen, Teva Pharma, Hoffmann-La Roche

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Neuromyelitis Optica Spectrum Disorder pipeline constitutes 15+ key companies continuously working towards developing 15+ Neuromyelitis Optica Spectrum Disorder treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Neuromyelitis Optica Spectrum Disorder Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Neuromyelitis Optica Spectrum Disorder Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Neuromyelitis Optica Spectrum Disorder Market.

Some of the key takeaways from the Neuromyelitis Optica Spectrum Disorder Pipeline Report:

Companies across the globe are diligently working toward developing novel Neuromyelitis Optica Spectrum Disorder treatment therapies with a considerable amount of success over the years.
Neuromyelitis Optica Spectrum Disorder companies working in the treatment market are Harbour BioMed, Reistone Biopharma, RemeGen, ENDECE, Aeterna Zentaris, Shanghai Pharmaceuticals Holding Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., Alexion Pharmaceuticals, and others, are developing therapies for the Neuromyelitis Optica Spectrum Disorder treatment

Emerging Neuromyelitis Optica Spectrum Disorder therapies in the different phases of clinical trials are- HBM9161, SHR1459, Telitacicept, NDC-1308, AIM Biologicals, B001, LP-168, Ravulizumab, and others are expected to have a significant impact on the Neuromyelitis Optica Spectrum Disorder market in the coming years.
In June 2022, Alexion Pharmaceuticals commenced a Phase II/III clinical trial, employing an open-label, historical-controlled, single-arm, multicenter approach to assess the effectiveness, pharmacokinetics, pharmacodynamics, and safety of ravulizumab in children and adolescents diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) who test positive for aquaporin-4 antibodies (AQP4-Ab [+]).
In June 2022, The Brazilian Health Regulatory Agency (ANVISA) granted approval for UPLIZNA as a standalone treatment intended for adult patients diagnosed with Neuromyelitis Optica Spectrum Disorder (NMOSD) who exhibit a positive test result for the AQP4-IgG biomarker.
In May 2022, The European Commission granted approval to UPLIZNA, a medication created by Horizon Therapeutics, as a standalone treatment for adult individuals diagnosed with neuromyelitis optica spectrum disorder (NMOSD). This approval encompasses all adult NMOSD patients, irrespective of their AQP4-IgG biomarker test results.

Neuromyelitis Optica Spectrum Disorder Overview

Neuromyelitis Optica Spectrum Disorder (NMOSD), also recognized as Devic disease, is a persistent condition affecting the brain and spinal cord, primarily characterized by inflammation in the optic nerve (optic neuritis) and the spinal cord (myelitis). The occurrence and frequency of NMOSD vary, with reported rates ranging from 0.05–0.40 and 0.52–4.4 per 100,000 individuals, respectively.

Get a Free Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutic Assessment-

https://www.delveinsight.com/report-store/neuromyelitis-optica-spectrum-disorder-nmosd-pipeline-insight

Emerging Neuromyelitis Optica Spectrum Disorder Drugs Under Different Phases of Clinical Development Include:

HBM9161: Harbour BioMed
SHR1459: Reistone Biopharma
Telitacicept: RemeGen
NDC-1308: ENDECE
AIM Biologicals: Aeterna Zentaris
B001: Shanghai Pharmaceuticals Holding Co., Ltd.
LP-168: Guangzhou Lupeng Pharmaceutical Company LTD.
Ravulizumab: Alexion Pharmaceuticals

Neuromyelitis Optica Spectrum Disorder Route of Administration

Neuromyelitis Optica Spectrum Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as

Intravenous
Oral
Subcutaneous
Molecule Type

Neuromyelitis Optica Spectrum Disorder Molecule Type

Neuromyelitis Optica Spectrum Disorder Products have been categorized under various Molecule types, such as

Immunoglobulin
Monoclonal antibodies
Protein
Recombinant fusion proteins
Small molecules
Vaccine
Product Type

Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics Assessment

Neuromyelitis Optica Spectrum Disorder Assessment by Product Type
Neuromyelitis Optica Spectrum Disorder By Stage and Product Type
Neuromyelitis Optica Spectrum Disorder Assessment by Route of Administration
Neuromyelitis Optica Spectrum Disorder By Stage and Route of Administration
Neuromyelitis Optica Spectrum Disorder Assessment by Molecule Type
Neuromyelitis Optica Spectrum Disorder by Stage and Molecule Type

DelveInsight’s Neuromyelitis Optica Spectrum Disorder Report covers around 15+ products under different phases of clinical development like

Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration

Further Neuromyelitis Optica Spectrum Disorder product details are provided in the report. Download the Neuromyelitis Optica Spectrum Disorder pipeline report to learn more about the emerging Neuromyelitis Optica Spectrum Disorder therapies

Some of the key companies in the Neuromyelitis Optica Spectrum Disorder Therapeutics Market include:

Key companies developing therapies for Neuromyelitis Optica Spectrum Disorder are – Hoffmann-La Roche Ltd, Horizon Therapeutics plc, TG Therapeutics, Opexa Therapeutics, Mitsubishi Tanabe Pharma, Remegen, Teva Pharma, TG Therapeutics, Astrazeneca, Harbour Biomed, and others.

Neuromyelitis Optica Spectrum Disorder Pipeline Analysis:

The Neuromyelitis Optica Spectrum Disorder pipeline report provides insights into

The report provides detailed insights about companies that are developing therapies for the treatment of Neuromyelitis Optica Spectrum Disorder with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuromyelitis Optica Spectrum Disorder Treatment.
Neuromyelitis Optica Spectrum Disorder key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Neuromyelitis Optica Spectrum Disorder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Neuromyelitis Optica Spectrum Disorder market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Neuromyelitis Optica Spectrum Disorder drugs and therapies

Neuromyelitis Optica Spectrum Disorder Pipeline Market Drivers

Increase in NMOSD prevalence, rising awareness among general population about NMOSD, emergence of novel therapies are some of the important factors that are fueling the Neuromyelitis Optica Spectrum Disorder Market.

Neuromyelitis Optica Spectrum Disorder Pipeline Market Barriers

However, dearth of skilled professionals and lack of healthcare infrastructure in developing economies, high costs for NMOSD treatment and other factors are creating obstacles in the Neuromyelitis Optica Spectrum Disorder Market growth.

Scope of Neuromyelitis Optica Spectrum Disorder Pipeline Drug Insight

Coverage: Global
Key Neuromyelitis Optica Spectrum Disorder Companies: Harbour BioMed, Reistone Biopharma, RemeGen, ENDECE, Aeterna Zentaris, Shanghai Pharmaceuticals Holding Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., Alexion Pharmaceuticals, and others
Key Neuromyelitis Optica Spectrum Disorder Therapies: HBM9161, SHR1459, Telitacicept, NDC-1308, AIM Biologicals, B001, LP-168, Ravulizumab, and others
Neuromyelitis Optica Spectrum Disorder Therapeutic Assessment: Neuromyelitis Optica Spectrum Disorder current marketed and Neuromyelitis Optica Spectrum Disorder emerging therapies
Neuromyelitis Optica Spectrum Disorder Market Dynamics: Neuromyelitis Optica Spectrum Disorder market drivers and Neuromyelitis Optica Spectrum Disorder market barriers

Request for Sample PDF Report for Neuromyelitis Optica Spectrum Disorder Pipeline Assessment and clinical trials

Table of Contents

1. Neuromyelitis Optica Spectrum Disorder Report Introduction

2. Neuromyelitis Optica Spectrum Disorder Executive Summary

3. Neuromyelitis Optica Spectrum Disorder Overview

4. Neuromyelitis Optica Spectrum Disorder- Analytical Perspective In-depth Commercial Assessment

5. Neuromyelitis Optica Spectrum Disorder Pipeline Therapeutics

6. Neuromyelitis Optica Spectrum Disorder Late Stage Products (Phase II/III)

7. Neuromyelitis Optica Spectrum Disorder Mid Stage Products (Phase II)

8. Neuromyelitis Optica Spectrum Disorder Early Stage Products (Phase I)

9. Neuromyelitis Optica Spectrum Disorder Preclinical Stage Products

10. Neuromyelitis Optica Spectrum Disorder Therapeutics Assessment

11. Neuromyelitis Optica Spectrum Disorder Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Neuromyelitis Optica Spectrum Disorder Key Companies

14. Neuromyelitis Optica Spectrum Disorder Key Products

15. Neuromyelitis Optica Spectrum Disorder Unmet Needs

16 . Neuromyelitis Optica Spectrum Disorder Market Drivers and Barriers

17. Neuromyelitis Optica Spectrum Disorder Future Perspectives and Conclusion

18. Neuromyelitis Optica Spectrum Disorder Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Neuromyelitis Optica Spectrum Disorder Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Remegen, Teva Pharma, Hoffmann-La Roche

Merkel Cell Carcinoma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Kartos Therapeutics, Immunomic Therapeutics, Neoimmunetech, Merck

“Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Merkel Cell Carcinoma, historical and forecasted epidemiology as well as the Merkel Cell Carcinoma market trends in the 7MM.

DelveInsight’s “Merkel Cell Carcinoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Merkel Cell Carcinoma, historical and forecasted epidemiology as well as the Merkel Cell Carcinoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Merkel Cell Carcinoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Merkel Cell Carcinoma Market Forecast

Some of the key facts of the Merkel Cell Carcinoma Market Report:

The Merkel Cell Carcinoma market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In March 2023, the US FDA granted approval for ZYNYZ (retifanlimab), a humanized monoclonal antibody that targets the programmed death receptor-1 (PD-1), designed to treat adults dealing with metastatic or recurring locally advanced Merkel cell carcinoma (MCC). The Biologics License Application (BLA) for ZYNYZ received accelerated approval from the US FDA for this particular indication, based on assessments of tumor response rate and the duration of response (DOR).
According to the “Skin Cancer Foundation,” Merkel cell carcinoma (MCC) is considerably rarer than melanoma, being approximately 40 times less common. It affects roughly one person per 130,000 individuals in the US. Annually, around 3,000 new cases of MCC are diagnosed in the US. Experts anticipate that this number will rise to approximately 3,250 cases diagnosed annually by the year 2025
As stated by merkelcell.org, Merkel cell carcinoma (MCC) is an uncommon and aggressive form of skin cancer, accounting for approximately 2,000 new cases reported annually in the United States.
According to the National Organization for Rare Disorders (NORD), around 60% of Merkel cell carcinoma (MCC) tumors develop in men. Over the last 15 years, there has been a threefold increase in its occurrence in the United States. Additionally, approximately one-third of those affected by MCC may face life-threatening consequences due to the disease
Key Merkel Cell Carcinoma Companies: Kartos Therapeutics, Immunomic Therapeutics, Neoimmunetech, EMD Serono Research, Merck Sharp & Dohme, Millennium Pharmaceutical, Bristol-Myers Squibb, Incyte Corporation, Immune Oncology Network, Sotio Biotech Inc, Regeneron Pharmaceuticals, and others
Key Merkel Cell Carcinoma Therapies: Navtemadlin (KRT-232), ITI-3000, NT-I7 (efineptakinalfa), Avelumab, Pembrolizumab, MLN0128, Nivolumab, KRT-232, Retifanlimab, NT-I7, CAR-GPC3 T Cells, vidutolimod, and others
The Merkel Cell Carcinoma epidemiology based on gender analyzed that Merkel Cell Carcinoma affects males and females equally
The Merkel Cell Carcinoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Merkel Cell Carcinoma pipeline products will significantly revolutionize the Merkel Cell Carcinoma market dynamics.

Merkel Cell Carcinoma Overview

Merkel Cell Carcinoma (MCC) is a rare and aggressive type of skin cancer that typically develops on sun-exposed areas of the body. It arises from Merkel cells, which are specialized skin cells responsible for the sense of touch. Merkel Cell Carcinoma tends to appear as firm, painless, flesh-colored or bluish-red nodules or lumps on the skin.

Get a Free sample for the Merkel Cell Carcinoma Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/merkel-cell-carcinoma-market

Merkel Cell Carcinoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Merkel Cell Carcinoma Epidemiology Segmentation:

The Merkel Cell Carcinoma market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Merkel Cell Carcinoma
Prevalent Cases of Merkel Cell Carcinoma by severity
Gender-specific Prevalence of Merkel Cell Carcinoma
Diagnosed Cases of Episodic and Chronic Merkel Cell Carcinoma

Download the report to understand which factors are driving Merkel Cell Carcinoma epidemiology trends @ Merkel Cell Carcinoma Epidemiology Forecast

Merkel Cell Carcinoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Merkel Cell Carcinoma market or expected to get launched during the study period. The analysis covers Merkel Cell Carcinoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Merkel Cell Carcinoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Merkel Cell Carcinoma Therapies and Key Companies

Navtemadlin (KRT-232): Kartos Therapeutics
ITI-3000: Immunomic Therapeutics
NT-I7 (efineptakinalfa): Neoimmunetech
Avelumab: EMD Serono Research
Pembrolizumab: Merck Sharp & Dohme
MLN0128: Millennium Pharmaceutical
Nivolumab: Bristol-Myers Squibb
KRT-232: Kartos Therapeutics
Retifanlimab: Incyte Corporation
NT-I7: Immune Oncology Network
CAR-GPC3 T Cells: Sotio Biotech Inc
vidutolimod: Regeneron Pharmaceuticals

Discover more about therapies set to grab major Merkel Cell Carcinoma market share @ Merkel Cell Carcinoma Treatment Landscape

Merkel Cell Carcinoma Market Strengths

Increased awareness and interest by the government and various organizations.

Merkel Cell Carcinoma Market Opportunities

Competitors are less so that can act as an opportunity for lead players to dominate the market.

Scope of the Merkel Cell Carcinoma Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Merkel Cell Carcinoma Companies: Kartos Therapeutics, Immunomic Therapeutics, Neoimmunetech, EMD Serono Research, Merck Sharp & Dohme, Millennium Pharmaceutical, Bristol-Myers Squibb, Kartos Therapeutics, Incyte Corporation, Immune Oncology Network, Sotio Biotech Inc, Regeneron Pharmaceuticals, and others
Key Merkel Cell Carcinoma Therapies: Navtemadlin (KRT-232), ITI-3000, NT-I7 (efineptakinalfa), Avelumab, Pembrolizumab, MLN0128, Nivolumab, KRT-232, Retifanlimab, NT-I7, CAR-GPC3 T Cells, vidutolimod, and others
Merkel Cell Carcinoma Therapeutic Assessment: Merkel Cell Carcinoma current marketed and Merkel Cell Carcinoma emerging therapies
Merkel Cell Carcinoma Market Dynamics: Merkel Cell Carcinoma market drivers and Merkel Cell Carcinoma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Merkel Cell Carcinoma Unmet Needs, KOL’s views, Analyst’s views, Merkel Cell Carcinoma Market Access and Reimbursement

To know more about Merkel Cell Carcinoma companies working in the treatment market, visit @ Merkel Cell Carcinoma Clinical Trials and Therapeutic Assessment

Table of Contents

1. Merkel Cell Carcinoma Market Report Introduction

2. Executive Summary for Merkel Cell Carcinoma

3. SWOT analysis of Merkel Cell Carcinoma

4. Merkel Cell Carcinoma Patient Share (%) Overview at a Glance

5. Merkel Cell Carcinoma Market Overview at a Glance

6. Merkel Cell Carcinoma Disease Background and Overview

7. Merkel Cell Carcinoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Merkel Cell Carcinoma

9. Merkel Cell Carcinoma Current Treatment and Medical Practices

10. Merkel Cell Carcinoma Unmet Needs

11. Merkel Cell Carcinoma Emerging Therapies

12. Merkel Cell Carcinoma Market Outlook

13. Country-Wise Merkel Cell Carcinoma Market Analysis (2019–2032)

14. Merkel Cell Carcinoma Market Access and Reimbursement of Therapies

15. Merkel Cell Carcinoma Market Drivers

16. Merkel Cell Carcinoma Market Barriers

17. Merkel Cell Carcinoma Appendix

18. Merkel Cell Carcinoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Merkel Cell Carcinoma Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Kartos Therapeutics, Immunomic Therapeutics, Neoimmunetech, Merck

Shanghai Yu Garden’s First Overseas Lantern Show Kicks Off in Paris

Yu Garden, which is renowned for the spectacular lantern show that it puts on each year in downtown Shanghai to celebrate the Lantern Festival that falls on the 15th day of the lunar new year, kicked off its first overseas lantern show on Dec. 15 in Paris, the same day that its extravaganza in Shanghai lit up.

The French Yu Garden Lantern Festival is being held in the Jardin d’Acclimatation for 72 days to Feb. 25 next year, and spans many important holidays such as Christmas, New Year’s Day, Chinese New Year, the Lantern Festival and Valentine’s Day.

Next year is the Year of the Dragon in the lunar calendar and many of the 60 large lantern sets and over 2,000 lanterns on display in Paris have a dragon theme. There will also be 350 performances, including Chinese martial arts and traditional acrobatics, will take place in the garden.

The full Shanghai extravaganza will start in late January and run for more than 40 days to the end of February.

French and Chinese dignitaries such as Lu Shaye, Chinese Ambassador to France, Ni Qiang, president of Yu Garden operator Shanghai Yuyuan Tourist Mart Group, Hubert Vedrine, former French Foreign Minister, Marc-Antoine Jamet, director of Jardin d’Acclimatation and secretary general of LVMH, light lanterns together with a group of children at the opening ceremony.

Giant lantern sets featuring mythical creatures from Chinese legends are on display.

The Zigzag Bridge and the Huxinting Teahouse, which are iconic areas of the Yu Garden in Shanghai, appear in lantern-form at the Paris event.

Lanterns of traditional Chinese Hanfu clothing light up one area of the event.

Visitors can queue up for a basket of Nanxiang steamed buns, a famous delicacy sold at the Yu Garden in Shanghai by a sixth-generation descendant of this intangible cultural heritage.

About Yicai Global

Launched in August 2016, Yicai Global is the English-language news service of Yicai Media Group, the financial news arm of Shanghai Media Group, which is one of China’s largest state-owned media conglomerates. Focused primarily on China’s business world, Yicai Global is dedicated to provide reliable and insightful information and analysis of the economy, finance, tech, startups, and entrepreneurs.

Media Contact
Company Name: Yicai Media Group
Contact Person: Zhu Liming
Email: Send Email
Country: China
Website: https://www.yicaiglobal.com/

Shanghai Jiao Tong Hosted 30th Birthday Bash for SJTU Educational Initiatives in Singapore

Shanghai Jiao Tong University, a renowned Chinese seat of higher learning, hosted the 30th anniversary celebrations for the SJTU Educational Initiatives at the Singapore & Antai Asia-Pacific Forum (Ⅲ) at the Antai Asia-Pacific Center in Singapore on Dec. 9.

The event is jointly organized by the SJTU Asia-Pacific Graduate Institute, SJTU Antai College of Economics & Management, and the Antai Asia-Pacific Center. The theme of the forum is ‘Sustainable development of the Association of Southeast Asian Nations amid uncertainties: business and industry revitalization.’

Yicai Media Group is a media partner of the forum.

SJTU launched the Master of Business Administration program in Singapore in 1993. SJTU Asia-Pacific Graduate Institute, the first overseas graduate center set up by a Chinese mainland university, was launched in 2002. It was registered as a non-profit organization in 2019 and its first brick-and-mortar education center opened at the Antai Asia-Pacific Center in the same year.

Antai College of Economics & Management is a core college of SJTU.

SJTU has trained more than 800 graduates for Singapore in the past 30 years and has made outstanding contributions to the business development of Singapore and the entire region covered by the Association of Southeast Asian Nations.

About Yicai Global

Media Contact
Company Name: Yicai Media Group
Contact Person: Zhu Liming
Email: Send Email
Country: China
Website: https://www.yicaiglobal.com/

Chinese Firms Are Becoming More Innovative, Enterprising, WIPO Director General Says

The number of Chinese intellectual property filings is the highest among all IP categories, meaning that Chinese companies are becoming more innovative and enterprising, according to the director general of the World IP Organization.

“China’s achievements in the Global Innovation Index, as well as its rankings in the technology classes, show that China is a country that pays a lot of attention to intellectual property,” Daren Tang told Yicai at the 20th Shanghai International IP Forum. Over the last 50 years, China has totally transformed its IP and innovation ecosystem, Tang noted.

China is the only middle-income economy in the GII top 30, ranking 12th, according to the WIPO’s GII released in September. Moreover, China has 24 Science and Technology clusters among the world’s top 100, ranking first before the United States, which has 21. The Shenzhen-Hong Kong-Guangzhou, Beijing, and Shanghai-Suzhou clusters ranked second, fourth, and fifth, respectively.

“Chinese companies are not just looking at IP as a form of registration or legal right, but they are using IPs to grow their business,” Tang said. “This is very good for the Chinese economy because as China pushes towards using science, technology, and innovation to grow its economy, IPs are very important for this strategy as IPs will protect the ideas and help them to be commercialized.”

At last year’s WIPO Global IP Awards, which celebrate enterprises and individuals making smart use of IPs for commercialization and bringing positive contributions to society, Shanghai-based light-emitting-diode technology developer Shylon Optoelectronics Technology was one of the two Chinese firms winning an award, which helped it receive many procurement contracts from the 2022 World Cup in Qatar, Tang pointed out, adding that two other companies from Shanghai also won an award this year.

WIPO teams discussed with shareholders, including top leaders from Guangdong province and Shanghai during their visit to China. “The WIPO will continue working with the Chinese government to support the use of IPs as a catalyst of growth and development not just for China but for all countries in the world,” Tang noted.

About Yicai Global

Media Contact
Company Name: Yicai Media Group
Contact Person: Zhu Liming
Email: Send Email
Country: China
Website: https://www.yicaiglobal.com/

Creative Boom 2023: Bond Pickleball Partners with Liven to Showcase the Immense Potential of Blending Art and Sports

In a groundbreaking collaboration, Bond Pickleball partners with internationally acclaimed artist and curator, Liven, to showcase the immense potential of blending art and sports. This collaboration is inspiring both pickleball enthusiasts and artists to explore the creative possibilities within this dynamic field.

Meet the Artist

Liven is a globally active artist and curator, a member of the Asia Pacific Young Artists Association, and a judge for the Asia Pacific Young Art Competition. Known for his work in Hong Kong, China, and Europe, he has participated in several international exhibitions. His recent shows at the Florence Contemporary Art Exchange, organized by the Italian National Art Association and presented by ISOLART Gallery, and at Notre Dame Week of Art have firmly established his position on the international art scene!

The Creative Concept Behind Liven

In the Bond Pickleball Planet, each member of the team has a unique personality. I aimed to express teamwork, mutual help, and warmth through the cute and playful characters. During the creative process, I carefully selected the most crucial elements while keeping the image simple and clear. For me, the warmth of the colour scale is represented by warm colours, with yellow being the most striking. This gives the overall image of the character a vibrant and visually captivating appearance. The design of the main character, Cubby, underwent numerous adjustments and modifications not less than 40 times, but none yielded the desired results. In the end, I returned to the essence of what I wanted to express: warmth. But how could I visualize warmth? That’s when I came up with the idea of a hug. By visualizing the warm feeling conveyed by the act of hugging, I associated it with a fluffy pet cat, which evokes a sense of warmth and comfort. Therefore, I molded the main image into a chubby character. And thus, the highly recognizable and joyful Cubby, radiating warmth, was born.

Bond Pickleball: Artistry, Customization, Professionalism

As a brand dedicated to propelling the innovative evolution of Bond Pickleball, we recognize the limitations of traditional equipment and pickleball paddle designs. Embracing the belief that pickleball is a game ripe with creativity and individuality, we aspire to provide every pickleball player with a platform to express their unique style on the court. Our commitment extends beyond functionality, as we aim to craft paddles that integrate art. We want to nurture the growth of pickleball by celebrating creativity, individuality, community, and excellence. We endeavour to cultivate a stadium environment infused with personality and creativity, delivering a distinct and immersive experience for pickleball players and spectators alike.

Further Collaboration in the Bond Pickleball Artist Program

The collaboration between Bond Pickleball and Liven unfolds as an exploration and innovation that allows art to seamlessly intertwine with pickleball. We break boundaries, broaden horizons, and redefine the relationship between these two diverse realms. This partnership offers pickleball enthusiasts and artists an extraordinary opportunity to join forces, exchange ideas, and co-create exceptional works. The Bond Pickleball Artist Program invites everyone to contribute their talents and leave an indelible mark on the unfolding narrative of art and pickleball. Become part of this transformative collaboration and contribute to the evolving pickleball story. Learn more about Bond Pickelaball Artist Program

For further details, explore the following link: https://bondpickleball.com/

Media Contact
Company Name: Bond Pickleball INC.
Contact Person: Koky Huang
Email: Send Email
Country: United States
Website: https://bondpickleball.com/

Hanley Investment Group Facilitates $5.1M Sale of New Raising Cane’s Drive-Thru in Santa Barbara County, Calif.

SANTA MARIA, Calif. – Hanley Investment Group Real Estate Advisors, a nationally recognized real estate brokerage and advisory firm specializing in retail property sales, announced today that the firm arranged the sale of a brand-new construction, single-tenant Raising Cane’s Chicken Fingers Double Drive-Thru restaurant within Santa Maria, California’s premier retail destination, Enos Ranch, for $5.1 million ($1,608 per square foot).

Hanley Investment Group’s Vice Presidents Alexander Moore and Sean Cox, along with Executive Vice President Kevin Fryman, represented the seller, College West Partners, L.P. of Tustin, California, and the buyer, a private investor based in Los Angeles.

“We closed escrow within 62 days from our listing date while eight other single-tenant Raising Cane’s were on the market in California. This is another great example of Hanley Investment Group’s ability to differentiate opportunities in the market through superior storytelling,” Moore highlighted. “We procured a direct all-cash investor with short due diligence and closing time frames who owned multiple Raising Cane’s restaurants in California and was not in a 1031 exchange.”

Cox added, “Single-tenant QSR drive-thrus leased to national corporate tenants continue to experience the highest demand from net-leased investors in today’s market. Buyers are willing to pay a premium for well-located, corporate-leased retail investments, and our success in facilitating this sale is a testament to that.”

Built in 2022 on a 0.80-acre pad, Raising Cane’s 3,172-square-foot freestanding restaurant is located at 485 Betteravia Road, within Enos Ranch, at the signalized intersection of Betteravia Road and College Drive (49,000 cars per day). This intersection provides direct freeway ramp access to U.S. Route 101 (69,000 cars per day).

Enos Ranch is a Class-A, 99% leased, 110-acre mixed-use development that attracts 6.5 million annual visitors. Enos Ranch features Costco, Lowe’s, multiple car dealerships, apartments, an elementary school, park and cultural center, Coast Hills Credit Union’s three-story campus, and best-in-class retailers and restaurants. Junior box anchor tenants include Aldi, Boot Barn, Guitar Center, Petco, Dick’s Sporting Goods, Old Navy, ULTA Beauty, HomeGoods, among others. Pad tenants include Chick-fil-A, Chipotle, Dutch Bros, Habit Burger, Juice It Up!, Firehouse Subs, Nick the Greek, Crumbl Cookies, Nothing Bundt Cakes, Urbane Café, Jack in the Box, Buffalo Wild Wings, Cracker Barrel and others.

Santa Maria, a significant shopping hub for surrounding communities, has a strong demographic profile, with 132,000 residents and an average household income of $96,000 within a five-mile radius. The regional trade area includes 371,000 residents, adding to its appeal as a destination.

Vandenberg Space Force Base, located within 15 minutes south of Santa Maria, contains 99,604 acres of land, operates approximately 16 launch facilities and complexes, and maintains the second largest airfield runway in the Department of Defense, which is 15,000 feet long. The base supports a population of over 18,000 people, including military personnel, family members, contractors and civilian employees.

Fryman added, “Raising Cane’s has established itself as one of the premier brands in the quick-service restaurant (QSR) sector among single-tenant investors. The rapidly expanding chain, with more than 700 locations nationwide and plans to open 100 restaurants in 2024, enhances its operations through its mobile app, takeout, dine-in options, and two drive-thru lanes.”

About Hanley Investment Group

Hanley Investment Group Real Estate Advisors is a real estate brokerage and advisory services company with over a $10.6 billion transaction track record that specializes in the sale of retail properties nationwide. Our expertise, proven track record, and unwavering dedication to putting clients’ needs first set us apart in the industry. Hanley Investment Group creates value by delivering exceptional results through the use of property-specific marketing strategies, cutting-edge technology, and local market knowledge. Our nationwide relationships with investors, developers, institutions, franchisees, brokers, and 1031 exchange buyers are unparalleled in the industry, translating into maximum exposure and pricing for each property. With unmatched service, Hanley Investment Group has redefined the experience of selling retail investment properties.

For more information, visit www.hanleyinvestment.com.

Media Contact
Company Name: Hanley Investment Group Real Estate Advisors
Contact Person: Alexander Moore, Vice President
Email: Send Email
Phone: 949.585.7614
Address:3500 East Coast Highway, Suite 100
City: Corona del Mar
State: California
Country: United States
Website: https://hanleyinvestmentgroup.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Hanley Investment Group Facilitates $5.1M Sale of New Raising Cane’s Drive-Thru in Santa Barbara County, Calif.

Bronchitis Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Hanlim Pharm, Ahn-Gook Pharma, Johnson & Johnson, PharmaKing, Yuhan Crp., Pfizer, Sanofi

“Bronchitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bronchitis, historical and forecasted epidemiology as well as the Bronchitis market trends in the 7MM.

DelveInsight’s “Bronchitis Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bronchitis, historical and forecasted epidemiology as well as the Bronchitis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Bronchitis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bronchitis Market Forecast

Some of the key facts of the Bronchitis Market Report:

The Bronchitis market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
In February 2022, Zydus, a division of Cadila Healthcare, announced that its U.S. subsidiary obtained the final approval from the US Food and Drug Administration (FDA) to commercialize roflumilast tablets in a strength of 500 mcg. Additionally, tentative approval was granted for roflumilast tablets. These tablets are designated for reducing the likelihood of chronic obstructive pulmonary disease (COPD) exacerbations in patients experiencing severe COPD associated with chronic bronchitis and a history of exacerbations.
In 2022, the combined number of acute bronchitis cases in children and adults was estimated to be around 19,517,000 and approximately 29,174,000 cases, respectively, across the seven major markets (7MM). It is projected that these figures will rise during the forecast period.
In 2022, the overall instances of acute bronchitis among children and adults were approximately 1,574,000 and roughly 2,819,000 cases, respectively, specifically within Germany. It is expected that these numbers will rise during the forecast period.
In 2022, the collective instances of chronic bronchitis reached an estimated ~26,954,000 cases across the seven major markets (7MM). Projections indicate an expected increase in these cases by the year 2032.
France had the highest number of acute bronchitis cases among the EU4 countries and the UK. These cases accounted for approximately 47% of the total instances of acute bronchitis in the EU4 and the UK in 2022.
Key Bronchitis Companies: Hanlim Pharm. Co., Ltd., Ahn-Gook Pharmaceutical, Johnson & Johnson, PharmaKing, Yuhan Corporation, Pfizer, Korea United Pharma, Hyundai Pharma, Vitaccess Ltd, Bayer, Sanofi, and others
Key Bronchitis Therapies: HL301(Experimental), Bronpass Tab, AGS (Experimental), levofloxacin, N02RS1 1200mg, YHD001, Azithromycin SR, KALOMIN™ Tab., Acebrophylline, Guafenesin tablets, Avelox (Moxifloxacin, BAY12-8039), Telithromycin, and others
The Bronchitis epidemiology based on gender analyzed that in most of the countries, male predominance Bronchitis was observed
The Bronchitis market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bronchitis pipeline products will significantly revolutionize the Bronchitis market dynamics.

Bronchitis Overview

Bronchitis is an inflammatory condition that affects the air passages in the lungs, specifically the bronchial tubes, causing them to become swollen and irritated. This inflammation leads to a persistent cough and increased production of mucus.

Get a Free sample for the Bronchitis Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/bronchitis-market

Bronchitis Epidemiology

Bronchitis Epidemiology Segmentation:

The Bronchitis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

Total Prevalence of Bronchitis
Prevalent Cases of Bronchitis by severity
Gender-specific Prevalence of Bronchitis
Diagnosed Cases of Episodic and Chronic Bronchitis

Download the report to understand which factors are driving Bronchitis epidemiology trends @ Bronchitis Epidemiology Forecast

Bronchitis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bronchitis market or expected to get launched during the study period. The analysis covers Bronchitis market uptake by drugs, patient uptake by therapies, and sales of each drug.

The report also covers the Bronchitis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bronchitis Therapies and Key Companies

HL301(Experimental): Hanlim Pharm. Co., Ltd.
Bronpass Tab.: Hanlim Pharm. Co., Ltd.
AGS (Experimental): Ahn-Gook Pharmaceutical
levofloxacin: Johnson & Johnson
N02RS1 1200mg: PharmaKing
YHD001: Yuhan Corporation
Azithromycin SR: Pfizer
KALOMIN™ Tab.: Korea United Pharma
Acebrophylline: Hyundai Pharma
Guafenesin tablets: Vitaccess Ltd
Avelox (Moxifloxacin, BAY12-8039): Bayer
Telithromycin: Sanofi

Discover more about therapies set to grab major Bronchitis market share @ Bronchitis Treatment Landscape

Scope of the Bronchitis Market Report

Study Period: 2019–2032
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Bronchitis Companies: Hanlim Pharm. Co., Ltd., Ahn-Gook Pharmaceutical, Johnson & Johnson, PharmaKing, Yuhan Corporation, Pfizer, Korea United Pharma, Hyundai Pharma, Vitaccess Ltd, Bayer, Sanofi, and others
Key Bronchitis Therapies: HL301(Experimental), Bronpass Tab, AGS (Experimental), levofloxacin, N02RS1 1200mg, YHD001, Azithromycin SR, KALOMIN™ Tab., Acebrophylline, Guafenesin tablets, Avelox (Moxifloxacin, BAY12-8039), Telithromycin, and others
Bronchitis Therapeutic Assessment: Bronchitis current marketed and Bronchitis emerging therapies
Bronchitis Market Dynamics: Bronchitis market drivers and Bronchitis market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Bronchitis Unmet Needs, KOL’s views, Analyst’s views, Bronchitis Market Access and Reimbursement

To know more about Bronchitis companies working in the treatment market, visit @ Bronchitis Clinical Trials and Therapeutic Assessment

Table of Contents

1. Bronchitis Market Report Introduction

2. Executive Summary for Bronchitis

3. SWOT analysis of Bronchitis

4. Bronchitis Patient Share (%) Overview at a Glance

5. Bronchitis Market Overview at a Glance

6. Bronchitis Disease Background and Overview

7. Bronchitis Epidemiology and Patient Population

8. Country-Specific Patient Population of Bronchitis

9. Bronchitis Current Treatment and Medical Practices

10. Bronchitis Unmet Needs

11. Bronchitis Emerging Therapies

12. Bronchitis Market Outlook

13. Country-Wise Bronchitis Market Analysis (2019–2032)

14. Bronchitis Market Access and Reimbursement of Therapies

15. Bronchitis Market Drivers

16. Bronchitis Market Barriers

17. Bronchitis Appendix

18. Bronchitis Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Bronchitis Market to Observe Impressive Growth During the Forecast Period (2023-2032), Evaluates DelveInsight | Hanlim Pharm, Ahn-Gook Pharma, Johnson & Johnson, PharmaKing, Yuhan Crp., Pfizer, Sanofi